PROTHENA CORP PUBLIC LTD CO cotiza a 8.43 USD y tiene una capitalización bursátil de $433M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatm…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.31 | $0.68 | $-0.46 |
| Estimado | $-0.38 | $-0.38 | $-0.30 | $-0.46 |
| Sorpresa | — | +18.4% | +326.7% | +0.0% |
| Métrica | PRTA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -2216.4% | -38.6% | -2177.8% |
| Net Margin | -2520.6% | -33.6% | -2487.0% |
| FCF Margin | — | -13.9% | — |
| ROE | -87.0% | -40.4% | -46.6% |
| ROA | -74.7% | -32.0% | -42.7% |
| Current Ratio | 7.72 | 2.84 | +4.88 |
| Debt / Equity | — | 0.28 | — |